Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Zibrofusidic acid** is a brominated derivative of fusidic acid, a steroidal antibiotic, with the chemical formula C31H47BrO6. It is a **small molecule** researched primarily as a research tool for studying bacterial multidrug efflux pumps due to its structural modification at the 24-position with a bromine atom, potentially altering its pharmacokinetic properties or resistance profile compared to parent fusidic acid. Fusidic acid inhibits bacterial protein synthesis by preventing the turnover of elongation factor G (EF-G) from the ribosome, primarily targeting Gram-positive bacteria like *Staphylococcus aureus*; zibrofusidic acid likely retains a similar **mechanism of action** but has been investigated in clinical trials for topical treatment of skin infections such as impetigo and secondarily infected traumatic lesions (SITL).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zibrofusidic acid.